Physician profile
Daniel Hwang
NPI 1629236344
$104,510.48
in general payments reported to CMS, 2019-2025
12 companies · $17K in 2025
The $17K reported for 2025 was more than what 93% of Ophthalmic Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $299).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $9,787 · 2021: $17K · 2022: $26K · 2023: $23K · 2024: $12K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Honoraria: $20K · Consulting Fee: $4,250 · Food and Beverage: $3,805 · Travel and Lodging: $2,868 · Education: $10.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,250.00 |
| Honoraria | $19,937.50 |
| Consulting Fee | $4,250.00 |
| Food and Beverage | $3,804.75 |
| Travel and Lodging | $2,868.15 |
| Education | $10.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $74,607.95 | 2019-2023 | Tepezza |
| Amgen INC. | $29,037.21 | 2024-2025 | Tepezza |
| Ani Pharmaceuticals, INC. | $239.55 | 2023-2024 | Purified Cortrophin Gel |
| Alimera Sciences, INC. | $127.49 | 2019 | |
| Allergan, INC. | $125.00 | 2019 | |
| Pfizer INC. | $111.97 | 2019 | |
| Medtronic USA, INC. | $98.31 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $50.83 | 2024 | Xdemvy |
| Biotissue Holdings INC. | $35.66 | 2020 | |
| Merz Pharmaceuticals, LLC | $29.19 | 2023 | Xeomin |
| Novartis Pharmaceuticals Corporation | $23.73 | 2023 | |
| Merz North America, INC. | $23.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.